HOPE Therapeutics Launches First-in-Florida Deployment Of Ampa ONE-D Protocol, Achieving Single-Day Remission Rates Up To 72% In Treatment-Resistant Depression

Author: Benzinga Newsdesk | November 10, 2025 08:14am

• ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device.
• HOPE is one of the first Ampa deployments nationwide and is now deployed at multiple HOPE locations in Florida, including Naples, Fort Myers, and Sarasota, with six locations planned by year-end 2025.
• HOPE Medical Director, Rebecca Cohen, MD, is first Ampa-certified psychiatrist in Florida.
• Ampa Health has reported nonrandomized results indicating 87% response and 72% remission from treatment resistant depression at 6 weeks with its FDA-cleared device combined with physician-prescribed D-cycloserine and lisdexamfetamine.

SARASOTA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) today announced initiation of patient care with for treatment-resistant depression with the Ampa one day (ONE-D) protocol. HOPE is the first to deploy the Ampa technology in Florida and one of the first deployments nationwide. The Ampa device differs from other Transcranial Magnetic Stimulation (TMS) treatments in that the peer-reviewed literature has reported a high rate of success (87% response and 72% remission) in nonrandomized trials when a single day of TMS treatment is combined with physician-prescribed D-cycloserine and lisdexamfetamine (note that neither of the drugs reported in the published results is FDA-approved for the stated indication).1 D-cycloserine was previously reported to substantially enhance the effectiveness of TMS in reducing depression and suicidality by more than two-fold in a placebo-controlled trial using a traditional TMS protocol.2   Additional supportive findings documenting the effect of D-cycloserine in enhancing the effect of TMS were recently published by a team of researchers led by Prof. Joshua Brown at Harvard's McLean hospital.3 Dr. Brown additionally serves as the President of the Clinical TMS Society.

The Ampa device is initially deployed at multiple HOPE clinic locations in Florida including Sarasota, Naples and Fort Myers, under the direction of Rebecca Cohen, MD, HOPE's Medical Director, with six locations in Florida planned by year-end 2025. The ONE-D protocol offers a new treatment paradigm to patients with severe depression who previously were required to undergo 90 days of TMS. D-cycloserine is an active component of NRX-101, a Breakthrough Therapy designated investigational drug that is available under an expanded access protocol (www.clinicaltrials.gov NCT05779267) and Federal and State Right to Try regulations.

Posted In: NRXP